Paul Ranson is a consultant at Morgan Lewis who focuses on the regulatory and commercial needs of the pharmaceutical, biotechnology, and medical devices sectors.
Paul’s regulatory experience covers both marketing authorization-related matters and market access, pricing, and reimbursement issues. His commercial work is concentrated on transactions with a high degree of industry specificity including collaborations and outsourcing transactions.
The European Union’s regulation of medical devices in Europe only began in the 1990s. Previously, member states acted independently, but the differing national requirements were replaced by EU directives including the 1993 Medical Devices Directive (MDD) and the 1998 In Vitro Diagnostics Directive (IVDD).
CampdenFB.com is a wholly owned subsidiary of Campden Wealth
© 2001-2022 CampdenFB.com. All rights reserved. Your use of this site is governed by the Terms and Conditions.